Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Penn State Milton S. Hershey Medical Center · Pennsylvania State University · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
587
total citations
- FWCI
- 26.75
- Percentile
- 100%
- References
- 38
Citations per year
Authors
19Topics & keywords
Topics
Keywords
- Zoledronic acid
- Denosumab
- Medicine
- Oncology
- Internal medicine
- Osteoporosis
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.